Short versus long radiation schedule for advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study compares two different schedules of radiation (a short course versus a longer course) followed by standard chemotherapy and immunotherapy for advanced rectal cancer. It aims to see which approach works best to shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of rectal cancer called locally advanced adenocarcinoma that is pMMR or MSS (this means it may respond well to immunotherapy).
- You have not had any prior treatment for your rectal cancer (like surgery, radiation, or chemotherapy).
- Your tumor is located no more than 10 cm (about 4 inches) from your anal opening.
- You are in good general health (able to do daily activities without help, with good blood, liver, and kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of short-course radiation, chemotherapy, and two types of immunotherapy (HLX07 and Serplulimab) before surgery for advanced rectal cancer. It aims to see if this approach helps shrink tumors and improve outcomes.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
This trial tests whether a short course of radiation followed by an immunotherapy drug (PD-L1 inhibitor) plus chemotherapy works as well as or better than a longer radiation course for locally advanced rectal cancer. The goal is to shrink tumors before surgery.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy before surgery for high-risk rectal cancer. The goal is to see if this combination shrinks the tumor more effectively and improves outcomes.
This trial tests a combination of short-course radiation, chemotherapy (capecitabine), and two immunotherapy drugs (PD-1 and CTLA-4 inhibitors) for people with early-stage rectal cancer who want to avoid surgery and keep their anus. The goal is to see if this treatment can shrink the tumor enough to avoid major surgery.
This study compares two different radiation therapy schedules for rectal cancer that hasn't spread to distant sites. Researchers want to see if a shorter treatment plan works as well as a longer one, potentially reducing side effects and treatment time.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.